Additional file 6 of Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancer

Supplementary Material 6: Additional file 6.xlsx– Summary of variants classified as VUS, VUS + and VUS++: Shows a list of patients and each variant classified as VUS, VUS + or VUS++. The table also includes the results from the point-based evaluation system. Abbreviations used: VUS = variant of unknown significance.